98%
921
2 minutes
20
Background: The excessive and prolonged use of any relevant material is known as substance abuse. The study's objective is to determine the epidemiology of substance abuse's growth in Iraq over the 4 years between 2020 and 2023.
Materials And Methods: A retrospective study was applied for the purpose of collecting the sample, as the study was epidemiological and related to substance abuse among Iraqis for 4 years from the beginning of 2020 to 2023. Participants' data were collected from records that were available in the Iraqi Ministry of Health and Environment for four consecutive years. The sample size was (22,767). The questionnaire was divided into two main parts. The first part included demographic information, including gender, target groups, and areas where substance abuse was prevalent, whereas the second part included the type of addictive substance and prevalence during the year. The data collected were analyzed using the "Statistical Package for Social Sciences (SPSS), version 27" method by entering the data package into the statistical program to determine the frequency and percentage.
Results: The study's findings demonstrated that over 90% of the sample was male and that about half of the sample suffered from alcohol addiction. In addition, Baghdad Governorate has the highest prevalence rate among the other governorates, estimated at about%20.9.
Conclusion: According to the results of the current study, about half of the sample abused alcohol. In contrast to the northern governorates of the nation, drug abuse was most common in the central and southern governorates of Iraq.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12327727 | PMC |
http://dx.doi.org/10.4103/jehp.jehp_1139_24 | DOI Listing |
JMIR Res Protoc
September 2025
Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
Background: In pediatric intensive care units, pain, sedation, delirium, and iatrogenic withdrawal syndrome (IWS) must be managed as interrelated conditions. Although clinical practice guidelines (CPGs) exist, new evidence needs to be incorporated, gaps in recommendations addressed, and recommendations adapted to the European context.
Objective: This protocol describes the development of the first patient- and family-informed European guideline for managing pain, sedation, delirium, and IWS by the European Society of Paediatric and Neonatal Intensive Care.
Cell Mol Biol (Noisy-le-grand)
September 2025
Associate Professor, School of Pharmacy, Desh Bhagat University, Mandi Gobindgarh-Punjab 147301, India.
Alcoholic fatty liver disease (AFLD) is a leading cause of chronic liver disease worldwide, contributing to significant morbidity and mortality. Despite its growing prevalence, no FDA-approved pharmacological treatments exist, leaving lifestyle modifications as the primary intervention. AFLD pathogenesis involves a complex interplay of lipid accumulation, oxidative stress, insulin resistance, and inflammation, highlighting the need for innovative therapeutic approaches.
View Article and Find Full Text PDFJ Stud Alcohol Drugs
September 2025
National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Background: Historically, cannabis use and cannabis use disorder (CUD) have been more prevalent among males. However, emerging evidence suggests cannabis use may be increasing faster among females in younger age groups. This study characterized changes in female versus male differences in cannabis use and CUD across age groups and time.
View Article and Find Full Text PDFObjectives: Azapirone-class drugs are partial 5-HT1A receptor agonists commonly used to treat anxiety disorders. Prior experimental studies have so far demonstrated that these drugs have low potential for dependence and problematic use and are considered safe treatment options compared with benzodiazepines. However, recent evidence suggesting the contrary raises concerns about their safety.
View Article and Find Full Text PDFCochrane Database Syst Rev
September 2025
Department of Family Medicine, University of Alberta, Edmonton, Alberta, Canada.
Background: Opioid use disorder (OUD) is commonly treated in specialized care settings with long-acting opioid agonists, also known as opioid agonist therapy, or OAT. Despite the rise in opioid use globally and evidence for a 50% reduction in mortality when OAT is employed, the proportion of people with OUD receiving OAT remains small. One initiative to improve the access and uptake of OAT could be to offer OAT in a primary care setting; primary care clinics are more numerous, might reduce the visibility and potential stigma of receiving treatment for OUD, and may facilitate the care of other medical conditions that are unrelated to OUD.
View Article and Find Full Text PDF